IBEX 35
10.904,90 +50,20 (+0,46%) Euro Stoxx 50
4.948,91 +27,43 (+0,56%) Dólar/Euro
1,0774 +0,0007 (+0,06%) Petróleo Brent
83,07 +0,62 (+0,75%) Oro
2.330,30 +21,70 (+0,94%) Bitcoin EUR
60.575,28 +1.392,88 (+2,35%)
Zai Lab Limited (ZLAB)
Después del cierre:
Zai Lab Limited
Jinchuang Plaza
Building 1, Fourth Floor 4560 Jinke Road Pudong
Shanghai 201210
China
86 21 6163 2588
https://www.zailaboratory.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 2175
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Ying Du Ph.D. | Founder, Chairperson & CEO | 1,7M | N/A | 1966 |
| Mr. Joshua L. Smiley | President & COO | 1,22M | N/A | 1970 |
| Dr. Rafael G. Amado M.D. | President and Head of Global Oncology Research & Development | 1,6M | N/A | 1964 |
| Dr. Yajing Chen Ph.D. | Chief Financial Officer | 624,56k | N/A | 1968 |
| Dr. Harald Reinhart M.D. | President and Head of Global Development for Neuroscience, Autoimmune & Infectious Diseases | 951,03k | 424,76k | 1952 |
| Dr. Peter Huang Ph.D. | Chief Scientific Officer | N/A | N/A | N/A |
| Ms. Christine Chiou | Senior VP & Head of Investor Relations | N/A | N/A | N/A |
| Mr. Frazor Titus Edmondson III, J.D. | Chief Legal Officer & Joint Corporate Secretary | 829k | N/A | 1966 |
| Ms. Ann E. Beasley J.D. | Chief Compliance Officer | N/A | N/A | N/A |
| Dr. Ning Xu M.D. | Executive VP & Head of Clinical Operations | N/A | N/A | 1965 |
Descripción
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.
Gobierno corporativo
El ISS Governance QualityScore de Zai Lab Limited, a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
